Regen BioPharma, Inc. (OTCMKTS:RGBP – Get Free Report) saw a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 42 shares. Based on an average trading volume of 12,600,992 shares, the days-to-cover ratio is currently 0.0 days.
Regen BioPharma Price Performance
RGBP stock remained flat at $0.00 during midday trading on Wednesday. The company had a trading volume of 5,600,800 shares, compared to its average volume of 16,743,381. Regen BioPharma has a 52-week low of $0.00 and a 52-week high of $0.04.
Regen BioPharma Company Profile
Regen BioPharma, Inc is a biotechnology company focused on developing regenerative medicine and immunotherapy technologies. Its research has included approaches intended to regulate stem-cell activity, restore damaged tissue, and modify immune responses associated with cancer and other diseases.
The company has publicly described several investigational programs, including HemaXellerate, a stem-cell-based approach studied for potential use in bone-marrow failure disorders; dCellVax, an experimental cancer-immunotherapy platform; and research involving NR2F6, an immune-regulatory target.
Featured Articles
- Five stocks we like better than Regen BioPharma
- Treasury Yields Haven’t Been This High Since 2007—3 ETFs to Watch
- 3 Healthcare Dividend Stocks Offering More Than Just Income
- AI Uncertainty Is Rising, But These 3 Chip ETFs Still Have Momentum
- Arhaus Has New Momentum—Could Other Furniture Stocks Be Next?
Receive News & Ratings for Regen BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regen BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
